Drug intelligence / Profile preview

prohibitin peptides

Development stage
Preclinical
Lead developer
H. Lee Moffitt Cancer Center & Research Institute
Modality
Peptides
Administration
Subcutaneous
01

Overview

Prohibitin peptides are synthetic peptides derived from the coiled-coil domain (amino acids 175-217) of the tumor suppressor protein prohibitin-1 (PHB1). These peptides, which include the 42-mer H1-6, 14-mers (H1-2, H3-4, H5-6), and 7-mers (H2, H5), are designed to mimic the E2F1-binding domain of prohibitin. By mimicking this domain, the peptides repress E2F1-mediated transcription, recruit histone deacetylase 1 (HDAC1), and arrest cell proliferation. Preclinical studies demonstrate that prohibitin peptides induce apoptosis in breast, lung, and prostate cancer cell lines, reduce the invasive capability of cancer cells, and inhibit angiogenesis in endothelial cells, while sparing normal epithelial cells.

Other names
H1-2H-1-2H 1-2H1-6H-1-6H 1-6H2H-2H 2H3-4H-3-4H 3-4H5H-5H 5H5-6H-5-6H 5-6prohibitin-derived peptides
02

Targets

HDAC1 (Histone Deacetylase 1)E2F1 (E2F Transcription Factor 1)

Beyond the preview

Go deeper on prohibitin peptides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prohibitin peptides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call